For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.

Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.

Why Investors Should Pay Attention to This Value Stock

Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks.

Bristol Myers Squibb (BMY)

New York-based Bristol-Myers Squibb is one of the leading global specialty biopharmaceutical companies focused on developing treatments targeting severe diseases. Blockbuster immuno-oncology drug Opdivo maintains momentum on consistent label expansions. The company’s efforts to revive its portfolio amid generic competition for legacy drugs like Revlimid, Pomalyst, Sprycel and Abraxane are impressive. Drugs like Reblozyl, Breyanzi, Camzyos and Opdualag stabilize its revenue base. Beyond oncology, the company offers essential immunology and cardiovascular drugs, such as Orencia and Eliquis, thereby diversifying its portfolio.

BMY sits at a Zacks Rank #3 (Hold), holds a Value Style Score of A, and has a VGM Score of A. Compared to the Medical - Biomedical and Genetics industry's P/E of 19.8X, shares of Bristol Myers Squibb are trading at a forward P/E of 6.8X. BMY also has a PEG Ratio of 1.4, a Price/Cash Flow ratio of 8X, and a Price/Sales ratio of 2X.

Many value investors pay close attention to a company's earnings as well. For BMY, 12 analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.14 to $6.89 per share for 2025. Per share BMY boasts an average earnings surprise of 20.2%.

BMY should be on investors' short lists because of its impressive earnings and valuation fundamentals, a good Zacks Rank, and strong Value and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bristol Myers Squibb Company (BMY):Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments